MycoTechnology
Mycelium fermentation company making flavor modulators and sweet proteins for food and beverage brands.
On the record
Checkpoint: Next priced financing round and first named CPG customer orders for Zukora/ClearHT
The call
Mycotechnology has real fermentation technology and long customer ties, but it has gone four years without a new priced round while betting its future on a sweetener that just started selling.
MycoTechnology uses special mold fermentation to create ingredients like sweeteners and flavorings for food companies. Big companies such as IFF, Givaudan, and Tate & Lyle already do similar work and have much more money and scale, so they could copy or buy MycoTechnology's recipes and customer list if they wanted to. The one thing that could save the company is if its new sweetener product called Zukora starts getting real orders from major food brands soon, or if it can raise new funding before its cash runs out, which could happen in the next year or so.
Why
01
AI pressure: None apparent. AI-driven compound discovery could speed rivals' formulation work, but no AI product is displacing Mycotech's fermented ingredients today. Could AI do the core job? Only partly.
02
Bigger players: IFF, Givaudan, Tate & Lyle, Ingredion. These flavor and sweetener majors already run competing fermentation and sweet-protein programs and can out-fund a slow launch. Could a giant copy it? Yes, easily.
03
What protects it. Patented fermentation strains, GRAS filings, and 200+ existing customer relationships that a new entrant would need years to rebuild.
What would change this call
MycoTechnology announces a priced equity round or bridge financing within 12 months. Shows whether investors back it at flat/up value or a distressed discount.
A named CPG brand confirms retail use of Zukora/ClearHT, not just a press release. Would show real commercial traction rather than marketing claims.
HHS finalizes tighter rules on self-affirmed GRAS status in 2026. Could delay or block Zukora's regulatory launch pathway.
A named CPG brand confirms retail use of Zukora/ClearHT, not just a press release. Would show real commercial traction rather than marketing claims.
HHS finalizes tighter rules on self-affirmed GRAS status in 2026. Could delay or block Zukora's regulatory launch pathway.
Key numbers
- Raised $217M+ across Series A-E
- Series E was $85M, closed March 2022
- ClearIQ ingredient sales grew 60% in 2024
Named risks
- No priced equity round since March 2022 Series E despite stated not-yet-profitable status.
- Three CEO changes in about 18 months signal leadership instability.
- HHS Secretary RFK Jr signaled tighter scrutiny of self-affirmed GRAS status used for ClearHT.
- Zukora/ClearHT commercial launch in July 2026 has no confirmed named CPG customer orders yet.
- Incumbents like IFF, Givaudan, Tate and Lyle could replicate or acquire around patented fermentation IP.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| IFF | contesting | MycoTechnology co-developed with IFF for Europe since 2022 rather than competing head-on |
| Tate and Lyle | contesting | New CEO Jordi Ferre joined from Tate and Lyle in Jan 2025, overlapping sweetener market focus |
| Infinite Roots | gaining on | Acquired Bosque Foods in May 2026, consolidating mycoprotein sector MycoTechnology exited in 2024 |
| Givaudan, Ingredion | contesting | Flavor and sweetener majors could fund competing molecules against MycoTechnology's patented strains |
Questions people ask
- Is MycoTechnology profitable in 2026?
- No. CEO Jordi Ferre described MycoTechnology in April 2025 as 'well-funded, but not yet profitable,' and no priced equity round or profitability announcement has followed since, with the company still leaning on its March 2022 Series E capital.
- Who owns MycoTechnology?
- MycoTechnology is privately held with no parent company, backed by investors including an Oman Investment Authority affiliated group, Tyson Ventures, Continental Grain, Bunge Ventures and Maple Leaf Foods, having raised roughly $217 to $220 million across Series A through E as of April 2025.
- How many CEOs has MycoTechnology had recently?
- Founder Alan Hahn was succeeded by Mike Leonard in December 2023, who departed in May 2024; CTO Ranjan Patnaik served as interim CEO until Jordi Ferre, ex-Tate & Lyle and PureCircle, took over in January 2025, three changes in about 13 months.
- Could AI replace MycoTechnology's fermentation business?
- Not directly. Its core work is wet-lab mycelial fermentation, a physical biomanufacturing process AI cannot perform, though AI-assisted molecule discovery could erode MycoTechnology's R&D speed advantage over incumbents developing competing flavor and sweetener compounds.
- Is MycoTechnology's biggest competitor IFF?
- IFF is currently a co-development partner rather than a rival, per a 2022 European partnership, but IFF, Givaudan, Tate & Lyle and Ingredion could replicate MycoTechnology's patented fermentation strains and GRAS-approved ingredients, making them latent competitive threats.
- What is Zukora and has it succeeded commercially?
- Zukora, also called ClearHT, is MycoTechnology's honey-truffle sweet protein made via precision fermentation; it got GRAS self-affirmation in April 2025 and reached commercial partnerships (Adorvia Biotechnology) by July 2026, but no named CPG customer orders have been publicly confirmed yet.
Timeline
- 2026-07-13Announces global collaboration with Adorvia Biotechnology for stevia blending and China ClearIQ distribution
- 2025-04-10ClearHT/Zukora honey truffle sweet protein receives GRAS self-affirmation from FEMA
- 2025-04-08CEO reveals 2024 discontinuation of alt-protein business, calls company well-funded but not yet profitable
- 2025-01Jordi Ferre, ex-Tate and Lyle and PureCircle, becomes CEO
- 2024-05CEO Mike Leonard departs; CTO Ranjan Patnaik becomes interim CEO
- 2024-02-07Launches Fermentation-as-a-Service offering with 300 to 90,000L capacity
- 2023-12Founder Alan Hahn succeeded as CEO by Mike Leonard
- 2022-03-30Closes $85M Series E led by Oman Investment Authority affiliated group, total funding tops $200M
- 2020Closes $39M Series D, bringing cumulative funding to $121M
- 2017-09-25Closes $35M Series B financing
Revision history
25 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- MycoTechnology, Inc., an Unreasonable company (2023-12-15)
- MycoTechnology discontinued alt protein biz last year, reveals CEO (2025-04-08)
- MycoTechnology Secures $35 Million Series B Financing (2017-09-25)
- MycoTechnology Raises $39M Series D for its Mushroom Fermentation Platform
- MycoTechnology secures $85m in latest funding round (2022-03-30)
- MycoTechnology - Overview, News & Similar companies (2026-06-06)
- Revenue, Competitors, Alternatives (2022-03-29)
- the vegan business magazine (MycoTechnology entry) (2024-03-05)
- MycoTechnology's honey truffle sweetener receives GRAS approval (2025-04-10)
- MycoTechnology (2024-02-07)
- MycoTechnology and Adorvia Biotechnology Announce Global Collaboration (2026-07-13)
- MycoTechnology 2026 Company Profile